Shares of NovoCure Ltd. (NASDAQ:NVCR) traded up 4.1% during trading on Monday . The stock traded as high as $12.05 and last traded at $12.04, with a volume of 218,629 shares trading hands. The stock had previously closed at $11.57.

Several analysts have recently commented on the stock. Wedbush reaffirmed an “outperform” rating and issued a $30.00 price objective on shares of NovoCure in a report on Wednesday, July 6th. Zacks Investment Research downgraded shares of NovoCure from a “hold” rating to a “sell” rating in a report on Friday, May 13th. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average target price of $28.57.

The stock has a 50 day moving average price of $11.44 and a 200 day moving average price of $13.27. The stock’s market cap is $1.00 billion.

NovoCure (NASDAQ:NVCR) last issued its quarterly earnings results on Monday, May 9th. The company reported ($0.42) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.33) by $0.09. The company had revenue of $13.10 million for the quarter, compared to the consensus estimate of $23.65 million. On average, analysts anticipate that NovoCure Ltd. will post ($1.38) EPS for the current fiscal year.

In related news, COO Michael J. Ambrogi sold 20,000 shares of NovoCure stock in a transaction that occurred on Wednesday, June 8th. The shares were sold at an average price of $12.24, for a total value of $244,800.00. Following the completion of the transaction, the chief operating officer now owns 324,084 shares in the company, valued at $3,966,788.16. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

A number of hedge funds recently added to or reduced their stakes in the company. Morgan Stanley bought a new stake in NovoCure during the fourth quarter worth $9,619,000. Century Capital Management LLC bought a new stake in NovoCure during the fourth quarter worth $2,970,000. Finally, Hartline Investment Corp bought a new stake in NovoCure during the fourth quarter worth $1,143,000.

NovoCure Limited is a commercial-stage oncology company. The Company is engaged in developing a therapy called TTFields for the treatment of solid tumor cancers. TTFields is a low-toxicity anti-mitotic treatment that uses low-intensity, intermediate frequency, alternating electric fields to exert physical forces on molecules inside cancer cells, disrupting the basic machinery for normal cell division, leading to cancer cell death.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.